Achieve Life Sciences GAAP EPS of -$0.28 misses by $0.02
Source: SeekingAlpha
2025-11-06 07:16:14 ET
More on Achieve Life Sciences
- Achieve: Expedited Review Of Cytisinicline Sets The Stage For Development Expansion
- Achieve Life Sciences: Promising Pipeline But High Risks Makes Me Hold For Now
- Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call Transcript
- Achieve Life Sciences Q3 2025 Earnings Preview
- Achieve, Disc, Revolution among winners of initial FDA national priority vouchers
Read the full article on Seeking Alpha
For further details see:
Achieve Life Sciences GAAP EPS of -$0.28 misses by $0.02
Achieve Life Sciences Inc.
NASDAQ: ACHV
ACHV Trading
4.47% G/L:
$5.37 Last:
453,265 Volume:
$5.35 Open:
ACHV Latest News
May 19, 2026 02:15:00 pm
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
May 12, 2026 07:05:00 am
Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma
May 12, 2026 07:00:00 am
Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates
ACHV Stock Data
$234,761,887
51,636,968
N/A
28
N/A
Biotechnology & Life Sciences
Healthcare
CA
Bothell
